Thrombolytic therapy for acute ischemic stroke

被引：51

作者：

Blakeley, Jaishri O. ^{[1
]}

Llinas, Rafael H. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21218 USA

来源：

JOURNAL OF THE NEUROLOGICAL SCIENCES | 2007年 / 261卷 / 1-2期

关键词：

acute ischemic stroke; thrombolytic therapy; revascularization; rt-PA; intra-arterial thrombolysis;

D O I：

10.1016/j.jns.2007.04.031

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

The treatment of acute stroke changed dramatically since the publication of the NINDS trail for IV rt-PA for acute stroke. While this was not the first trial, it was the first positive trial. Subsequently there has been an explosion in acute treatment modalities since the NINDS trial showed that acute stroke treatment is feasible. The following chapter reviews the thrombolysis trials, the inclusion and exclusion criteria of intravenous and intra-arterial use of pharmacologic and mechanical thrombolysis in acute ischemic stroke. Also discussed are the new pharmacotherapies and mechanical devices that will hopefully expand the treatment window and make thrombolysis safer and more effective. (C) 2007 Elsevier B.V. All rights reserved.

引用

页码：55 / 62

页数：8

共 37 条

[1]

Intravenous tissue-type plasminogen activator for treatment of acute stroke - The standard treatment with alteplase to reverse stroke (STARS) study [J].

Albers, GW ;

Bates, VE ;

Clark, WM ;

Bell, R ;

Verro, P ;

Hamilton, SA .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (09) :1145-1150

[2]

International Society of Hypertension (ISH): Statement on the management of blood pressure in acute stroke [J].

Bath, P ;

Chalmers, J ;

Powers, W ;

Beilin, L ;

Davis, S ;

Lenfant, C ;

Mancia, G ;

Neal, B ;

Whitworth, J ;

Zanchetti, A .

JOURNAL OF HYPERTENSION, 2003, 21 (04) :665-672

[3]

Becker KJ, 1996, AM J NEURORADIOL, V17, P255

[4]

Generalized efficacy of t-PA for acute stroke - Subgroup analysis of the NINDS t-PA stroke trial [J].

Brott, T ;

Broderick, J ;

Kothari, R ;

ODonoghue, M ;

Barsan, W ;

Tomsick, T ;

Spilker, J ;

Miller, R ;

Sauerbeck, L ;

Farrell, J ;

Kelly, J ;

Perkins, T ;

Miller, R ;

McDonald, T ;

Rorick, M ;

Hickey, C ;

Armitage, J ;

Perry, C ;

Thalinger, K ;

Rhude, R ;

Schill, J ;

Becker, PS ;

Heath, RS ;

Adams, D ;

Reed, R ;

Klei, M ;

Hughes, A ;

Anthony, J ;

Baudendistel, D ;

Zadicoff, C ;

Rymer, M ;

Bettinger, I ;

Laubinger, P ;

Schmerler, M ;

Meiros, G ;

Lyden, P ;

Dunford, J ;

Zivin, J ;

Rapp, K ;

Babcock, T ;

Daum, P ;

Persona, D ;

Brody, M ;

Jackson, C ;

Lewis, S ;

Liss, J ;

Mahdavi, Z ;

Rothrock, J ;

Tom, T ;

Zweifler, R .

STROKE, 1997, 28 (11) :2119-2125

[5]

Admission glucose level and clinical outcomes in the NINDS rt-PA Stroke Trial [J].

Bruno, A ;

Levine, SR ;

Frankel, MR ;

Brott, TG ;

Lin, Y ;

Tilley, BC ;

Lyden, PD ;

Broderick, JP ;

Kwiatkowski, TG ;

Fineberg, SE .

NEUROLOGY, 2002, 59 (05) :669-674

[6]

CANDELISE L, 1995, LANCET, V346, P1509

[7]

Intravenous tissue plasminogen activator for acute ischemic stroke: Feasibility, safety, and efficacy in the first year of clinical practice [J].

Chiu, D ;

Krieger, D ;

Villar-Cordova, C ;

Kasner, SE ;

Morgenstern, B ;

Bratina, PL ;

Yatsu, FM ;

Grotta, JC .

STROKE, 1998, 29 (01) :303-303

[8]

Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial [J].

Clark, WM ;

Wissman, S ;

Albers, GW ;

Jhamandas, JH ;

Madden, KP ;

Hamilton, S .

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 282 (21) :2019-2026

[9]

*CLOTBUST INV, 2001, NEW ENGL J MED, V351, P2154

[10]

*CLOTBUST INV, 2001, J NEUROIMAGING, V14, P113

← 1 2 3 4 →